JOP20200214A1 - تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها - Google Patents

تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Info

Publication number
JOP20200214A1
JOP20200214A1 JOP/2020/0214A JOP20200214A JOP20200214A1 JO P20200214 A1 JOP20200214 A1 JO P20200214A1 JO P20200214 A JOP20200214 A JO P20200214A JO P20200214 A1 JOP20200214 A1 JO P20200214A1
Authority
JO
Jordan
Prior art keywords
polysaccharide
methods
typhi
diseases
preparation
Prior art date
Application number
JOP/2020/0214A
Other languages
English (en)
Inventor
Nikhil Dattatray Avalaskar
Sambhaji Shankar Pisal
Anil Pirajirao Taklikar
Dattatreya Sarma Annamraju
Vishal Bharat Chavan
Yogesh Tukaram Hundekari
Sunil Kumar Goel
Rajeev Mhalasakant Dhere
Chandrashekhar Dwarkanath Kamat
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of JOP20200214A1 publication Critical patent/JOP20200214A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الكشف الحالي بتركيبات لقاح مترافق مع بروتين عديد السكاريد أحادي التكافؤ ومتعدد التكافؤ جديدة مولدة للمناعة تشتمل على عديد سكاريد مُختار من Salmonella serovar السلالات S. typhi؛ S. paratyphi A؛ S. typhimurium و S. enteritidis وطرق بديلة مُحسنة لتخمير عديد السكاريد،، تنقية عديد السكاريد، واقتران البروتين بعديد السكاريد، وصيغة مستقرة. يتعلق الكشف الحالي أيضًا بطرق لتحفيز الاستجابة المناعية في خاضعين ضد Salmonella typhi والأمراض غير المرتبطة بالتيفويد و/ أو لتقليل أو الوقاية من Salmonella typhi والأمراض غير المرتبطة بالتيفويد في خاضعين يستخدمون التركيبات التي تم الكشف عنها في هذا الطلب. يُنتج اللقاح أجسامًا مضادة للبكتريا ويُعد مفيداً في الوقاية من التهاب المعدة والأمعاء والحمى المعوية والتيفويدية.
JOP/2020/0214A 2019-09-03 2019-09-03 تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها JOP20200214A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03

Publications (1)

Publication Number Publication Date
JOP20200214A1 true JOP20200214A1 (ar) 2021-03-03

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0214A JOP20200214A1 (ar) 2019-09-03 2019-09-03 تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Country Status (23)

Country Link
US (2) US20230149524A1 (ar)
EP (2) EP4249061A3 (ar)
JP (2) JP7732974B2 (ar)
KR (2) KR20220087437A (ar)
CN (1) CN114728053A (ar)
AR (1) AR119884A1 (ar)
AU (1) AU2020343943A1 (ar)
BR (1) BR112022003892A2 (ar)
CA (1) CA3149972A1 (ar)
CO (1) CO2022003789A2 (ar)
CR (1) CR20220132A (ar)
EC (1) ECSP22031077A (ar)
GB (2) GB2629746B (ar)
GE (2) GEAP202515919A (ar)
IL (1) IL291006B2 (ar)
JO (1) JOP20200214A1 (ar)
MA (1) MA56283A1 (ar)
MX (1) MX2022002693A (ar)
PE (1) PE20221442A1 (ar)
PH (1) PH12022550525A1 (ar)
PY (1) PY2051122A (ar)
WO (1) WO2021044436A2 (ar)
ZA (1) ZA202203368B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021710A1 (en) * 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025217253A1 (en) * 2024-04-12 2025-10-16 Neogen Corporation Neutralizing compositions and related methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1998026799A1 (en) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
CA2836140C (en) * 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
IN2012MU00206A (ar) * 2012-01-20 2013-08-09
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN102935226B (zh) 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
KR102447303B1 (ko) * 2013-08-24 2022-09-23 브하라트 바이오테크 인터내셔날 리미티드 박테리아성 백신 및 그의 제조방법
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
MY183392A (en) * 2015-07-04 2021-02-18 Bharat Biotech Int Ltd Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
AU2017316768B2 (en) 2016-08-26 2024-04-11 Serum Institute Of India Private Limited Multivalent vaccine composition
MD20190088A2 (ro) * 2017-05-05 2020-04-30 Serum Institute Of India Private Limited Metodă de eliminare a impurităţilor din preparatele pe bază de polizaharide capsulare bacteriene
BR112020000999A2 (pt) 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CA3115803A1 (en) 2018-10-12 2020-04-16 Serum Institute Of India Private Ltd. Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
CN113271967A (zh) * 2018-11-10 2021-08-17 巴拉特生物技术国际有限公司 多价糖缀合物免疫原性组合物

Also Published As

Publication number Publication date
CR20220132A (es) 2022-05-06
EP4249061A2 (en) 2023-09-27
CN114728053A (zh) 2022-07-08
IL291006B2 (en) 2026-03-01
CO2022003789A2 (es) 2022-04-19
JP2022546763A (ja) 2022-11-08
US20230149524A1 (en) 2023-05-18
ECSP22031077A (es) 2022-05-31
JP2024178271A (ja) 2024-12-24
MA56283A1 (fr) 2023-01-31
IL291006A (en) 2022-05-01
CA3149972A1 (en) 2021-03-11
BR112022003892A2 (pt) 2022-05-24
ZA202203368B (en) 2022-05-25
GB2629746A (en) 2024-11-06
PH12022550525A1 (en) 2023-03-20
PE20221442A1 (es) 2022-09-21
IL291006B1 (en) 2025-11-01
GEP20257808B (en) 2025-10-27
AU2020343943A1 (en) 2022-03-24
GB2629746B (en) 2025-01-29
WO2021044436A3 (en) 2021-05-27
JP7732974B2 (ja) 2025-09-02
MX2022002693A (es) 2022-07-12
EP4025246A2 (en) 2022-07-13
GB2603362B (en) 2025-01-15
US20250134980A1 (en) 2025-05-01
GB2603362A (en) 2022-08-03
WO2021044436A2 (en) 2021-03-11
PY2051122A (es) 2021-08-11
GB202204276D0 (en) 2022-05-11
EP4249061A3 (en) 2023-11-15
GEAP202515919A (en) 2025-05-27
AR119884A1 (es) 2022-01-19
KR20240155975A (ko) 2024-10-29
KR20220087437A (ko) 2022-06-24

Similar Documents

Publication Publication Date Title
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
JOP20210148A1 (ar) تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
Mitra et al. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis
RU2015106917A (ru) Везикулы наружной мембраны
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
Etkin et al. Studies on enterotoxin from Escherichia coli associated with acute diarrhea in man
ECSP22031077A (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
US7754227B2 (en) Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EA202190914A1 (ru) Иммуногенные композиции
RU2013145547A (ru) Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий
Amini et al. Evaluation of the immunogenicity of diphtheria toxoid conjugated to salmonella typhimurium-derived OPS in a mouse model: a potential vaccine candidate against salmonellosis
Patil Cellulitis due to Salmonella infantis
MX2015017677A (es) Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas.
Rivera-Patron et al. Quillaja brasiliensis leaf saponins and their nanoparticles are strong inducers of early immune responses
Singh et al. Antigenic competition among differentO'antigens of Salmonella enterica subspecies enterica serovars during hyperimmunization in pony mares
Roe et al. Vaccination against Klebsiella aerogenes
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
Cooper et al. Studies in Dysentery Vaccination: V. Immunization of Mice with Vaccine of Shigella Sonnei Administered by Gavage
Saxena et al. Bacterial Antigens and Antisera Section Bureau of Biologics, Health and Welfare Canada
Suzuki et al. On Immunization Against Typhoid Fever with Heterobacterigen
Szu et al. Escherichia coli O157
DK151086A (da) Klebsiella-vaccine paa basis af rensede kapselformede polysaccharider og fremgangsmaade til fremstilling af en saadan vaccine